These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 28729361)

  • 1. CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects.
    Thomas T; Zhou H; Karmally W; Ramakrishnan R; Holleran S; Liu Y; Jumes P; Wagner JA; Hubbard B; Previs SF; Roddy T; Johnson-Levonas AO; Gutstein DE; Marcovina SM; Rader DJ; Ginsberg HN; Millar JS; Reyes-Soffer G
    Arterioscler Thromb Vasc Biol; 2017 Sep; 37(9):1770-1775. PubMed ID: 28729361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein.
    Reyes-Soffer G; Millar JS; Ngai C; Jumes P; Coromilas E; Asztalos B; Johnson-Levonas AO; Wagner JA; Donovan DS; Karmally W; Ramakrishnan R; Holleran S; Thomas T; Dunbar RL; deGoma EM; Rafeek H; Baer AL; Liu Y; Lassman ME; Gutstein DE; Rader DJ; Ginsberg HN
    Arterioscler Thromb Vasc Biol; 2016 May; 36(5):994-1002. PubMed ID: 26966279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia.
    Teramoto T; Daida H; Ikewaki K; Arai H; Maeda Y; Nakagomi M; Shirakawa M; Watanabe Y; Kakikawa T; Numaguchi H; Johnson-Levonas AO; Blaustein RO
    Atherosclerosis; 2017 Jun; 261():69-77. PubMed ID: 28478132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.
    Millar JS; Reyes-Soffer G; Jumes P; Dunbar RL; deGoma EM; Baer AL; Karmally W; Donovan DS; Rafeek H; Pollan L; Tohyama J; Johnson-Levonas AO; Wagner JA; Holleran S; Obunike J; Liu Y; Ramakrishnan R; Lassman ME; Gutstein DE; Ginsberg HN; Rader DJ
    J Clin Invest; 2015 Jun; 125(6):2510-22. PubMed ID: 25961461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study.
    Gotto AM; Kher U; Chatterjee MS; Liu Y; Li XS; Vaidya S; Cannon CP; Brinton EA; Moon JE; Shah S; Dansky HM; Mitchel Y; Barter P;
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):543-9. PubMed ID: 24737712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.
    Krauss RM; Pinto CA; Liu Y; Johnson-Levonas AO; Dansky HM
    J Clin Lipidol; 2015; 9(1):93-102. PubMed ID: 25670366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial.
    Brinton EA; Kher U; Shah S; Cannon CP; Davidson M; Gotto AM; Ashraf TB; McCrary Sisk C; Dansky H; Mitchel Y; Barter P;
    J Clin Lipidol; 2015; 9(1):65-71. PubMed ID: 25670362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
    Ballantyne CM; Shah S; Kher U; Hunter JA; Gill GG; Cressman MD; Ashraf TB; Johnson-Levonas AO; Mitchel YB
    Am J Cardiol; 2017 Feb; 119(3):388-396. PubMed ID: 27956003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
    Bloomfield D; Carlson GL; Sapre A; Tribble D; McKenney JM; Littlejohn TW; Sisk CM; Mitchel Y; Pasternak RC
    Am Heart J; 2009 Feb; 157(2):352-360.e2. PubMed ID: 19185645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia.
    Arai H; Teramoto T; Daida H; Ikewaki K; Maeda Y; Nakagomi M; Shirakawa M; Kakikawa T; Numaguchi H; Johnson-Levonas AO; Vaidya S; Blaustein RO
    Atherosclerosis; 2016 Jun; 249():215-23. PubMed ID: 27131642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease.
    ; Bowman L; Hopewell JC; Chen F; Wallendszus K; Stevens W; Collins R; Wiviott SD; Cannon CP; Braunwald E; Sammons E; Landray MJ
    N Engl J Med; 2017 Sep; 377(13):1217-1227. PubMed ID: 28847206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E.
    Millar JS; Lassman ME; Thomas T; Ramakrishnan R; Jumes P; Dunbar RL; deGoma EM; Baer AL; Karmally W; Donovan DS; Rafeek H; Wagner JA; Holleran S; Obunike J; Liu Y; Aoujil S; Standiford T; Gutstein DE; Ginsberg HN; Rader DJ; Reyes-Soffer G
    J Lipid Res; 2017 Jun; 58(6):1214-1220. PubMed ID: 28314859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study.
    Kastelein JJ; Besseling J; Shah S; Bergeron J; Langslet G; Hovingh GK; Al-Saady N; Koeijvoets M; Hunter J; Johnson-Levonas AO; Fable J; Sapre A; Mitchel Y
    Lancet; 2015 May; 385(9983):2153-61. PubMed ID: 25743173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anacetrapib: hope for CETP inhibitors?
    Gurfinkel R; Joy TR
    Cardiovasc Ther; 2011 Oct; 29(5):327-39. PubMed ID: 20406242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies.
    Krishna R; Anderson MS; Bergman AJ; Jin B; Fallon M; Cote J; Rosko K; Chavez-Eng C; Lutz R; Bloomfield DM; Gutierrez M; Doherty J; Bieberdorf F; Chodakewitz J; Gottesdiener KM; Wagner JA
    Lancet; 2007 Dec; 370(9603):1907-14. PubMed ID: 18068514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Cholesteryl Ester Transfer Protein Preserves High-Density Lipoprotein Cholesterol and Improves Survival in Sepsis.
    Trinder M; Wang Y; Madsen CM; Ponomarev T; Bohunek L; Daisely BA; Julia Kong H; Blauw LL; Nordestgaard BG; Tybjærg-Hansen A; Wurfel MM; Russell JA; Walley KR; Rensen PCN; Boyd JH; Brunham LR
    Circulation; 2021 Mar; 143(9):921-934. PubMed ID: 33228395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of inhibition of cholesteryl ester transfer protein with anacetrapib: the DEFINE study.
    Gotto AM; Moon JE
    Expert Rev Cardiovasc Ther; 2012 Aug; 10(8):955-63. PubMed ID: 23030283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anacetrapib, a cholesteryl ester transfer protein inhibitor.
    Hooper AJ; Burnett JR
    Expert Opin Investig Drugs; 2012 Jan; 21(1):103-9. PubMed ID: 22191425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib.
    Miyares MA; Davis K
    Vasc Health Risk Manag; 2012; 8():483-93. PubMed ID: 22977305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase.
    Simic B; Mocharla P; Crucet M; Osto E; Kratzer A; Stivala S; Kühnast S; Speer T; Doycheva P; Princen HM; van der Hoorn JW; Jukema JW; Giral H; Tailleux A; Landmesser U; Staels B; Lüscher TF
    Atherosclerosis; 2017 Feb; 257():186-194. PubMed ID: 28152406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.